This work may not be copied, distributed, displayed, published, reproduced, transmitted, modified, posted, sold, licensed, or used for commercial purposes. By downloading this file, you are agreeing to the publisher’s Terms & Conditions.


Introduction. Ziprasidone in Schizophrenia: From Acute Treatment to Long-Term Management

John M. Kane, MD

Published: December 1, 2003

Article Abstract

Because this piece has no abstract, we have provided for your benefit the first 3 sentences of the full text.

Schizophrenia is a highly complex, chronic, often lifelong, mental illness that severely compromises social, intellectual, and occupational functioning. About 1% ofthe population will develop schizophrenia, and annuallymore than 2 million Americans suffer from the disorder.1People with schizophrenia on average live 15 fewer yearsthan individuals in the general population, dying prematurely of natural (e.g., cardiovascular and respiratory diseases) as well as unnatural causes (primarily suicide).2‘ ‹

Some JCP and PCC articles are available in PDF format only. Please click the PDF link at the top of this page to access the full text.

Related Articles

Volume: 64

Quick Links: Schizophrenia and Schizoaffective Disorders


Sign-up to stay
up-to-date today!


Already registered? Sign In

Case Report

Safety and Tolerability of Concomitant Intranasal Esketamine Treatment With Irreversible, Nonselective MAOIs: A Case Series

Three cases suggest that concomitant use of intranasal esketamine with an irreversible, nonselective MAOI is safe in...